These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7506299)

  • 1. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera.
    Vella C; Ferguson M; Dunn G; Meloen R; Langedijk H; Evans D; Minor PD
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2603-7. PubMed ID: 7506299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response.
    Cleveland SM; Buratti E; Jones TD; North P; Baralle F; McLain L; McInerney T; Durrani Z; Dimmock NJ
    Virology; 2000 Jan; 266(1):66-78. PubMed ID: 10612661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies.
    Evans DJ; McKeating J; Meredith JM; Burke KL; Katrak K; John A; Ferguson M; Minor PD; Weiss RA; Almond JW
    Nature; 1989 Jun; 339(6223):385-8, 340. PubMed ID: 2542797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.
    Conley AJ; Kessler JA; Boots LJ; Tung JS; Arnold BA; Keller PM; Shaw AR; Emini EA
    Proc Natl Acad Sci U S A; 1994 Apr; 91(8):3348-52. PubMed ID: 7512731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epitopes of HIV-1 glycoproteins recognized by the human immune system.
    Laal S; Zolla-Pazner S
    Chem Immunol; 1993; 56():91-111. PubMed ID: 7680869
    [No Abstract]   [Full Text] [Related]  

  • 10. Properties of a neutralizing antibody that recognizes a conformational form of epitope ERDRD in the gp41 C-terminal tail of human immunodeficiency virus type 1.
    Cleveland SM; Jones TD; Dimmock NJ
    J Gen Virol; 2000 May; 81(Pt 5):1251-60. PubMed ID: 10769067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.
    Zhang G; Chen YH
    Immunobiology; 2003; 207(4):259-64. PubMed ID: 12952348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.
    Blish CA; Nguyen MA; Overbaugh J
    PLoS Med; 2008 Jan; 5(1):e9. PubMed ID: 18177204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus.
    McLain L; Durrani Z; Wisniewski LA; Porta C; Lomonossoff GP; Dimmock NJ
    Vaccine; 1996 Jun; 14(8):799-810. PubMed ID: 8817828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S; Julien JP; Isenman DE; Kunert R; Katinger H; Pai EF
    J Mol Biol; 2008 Oct; 382(4):910-9. PubMed ID: 18692506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.
    Purtscher M; Trkola A; Gruber G; Buchacher A; Predl R; Steindl F; Tauer C; Berger R; Barrett N; Jungbauer A
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1651-8. PubMed ID: 7888224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus.
    McLain L; Porta C; Lomonossoff GP; Durrani Z; Dimmock NJ
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):327-34. PubMed ID: 7786579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine monoclonal antibodies directed against the transmembrane protein gp41 of human immunodeficiency virus type 1 enhance its infectivity.
    Niedrig M; Bröker M; Walter G; Stüber W; Harthus HP; Mehdi S; Gelderblom HR; Pauli G
    J Gen Virol; 1992 Apr; 73 ( Pt 4)():951-4. PubMed ID: 1378882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
    Nelson JD; Kinkead H; Brunel FM; Leaman D; Jensen R; Louis JM; Maruyama T; Bewley CA; Bowdish K; Clore GM; Dawson PE; Frederickson S; Mage RG; Richman DD; Burton DR; Zwick MB
    Virology; 2008 Jul; 377(1):170-83. PubMed ID: 18499210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.